Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6430)
All Articles published online
|
Publishing Process of This Article
|
Oct 28, 2014 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Chen RY, Xu B, Chen SF, Chen SS, Zhang T, Ren J, Xu J. Effect of oridonin-mediated hallmark changes on inflammatory pathways in human pancreatic cancer (BxPC-3) cells. World J Gastroenterol 2014; 20(40): 14895-14903 [PMID: 25356049 DOI: 10.3748/wjg.v20.i40.14895] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i40/14895.htm |
| Number | Citing Articles |
| 1 |
Yuanyuan Zhang, Shaohua Wang, Mengmeng Dai, Jijuan Nai, Liqiao Zhu, Huagang Sheng. Solubility and Bioavailability Enhancement of Oridonin: A Review. Molecules 2020; 25(2): 332 doi: 10.3390/molecules25020332
|
| 2 |
Yanhua Zhang, Hui Xu, Yue Li, Yang Sun, Xiaochun Peng. Advances in the treatment of pancreatic cancer with traditional Chinese medicine. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1089245
|
| 3 |
Zhifang Gui, Feng Luo, Yayang Yang, Can Shen, Shuquan Li, Jian Xu. Oridonin inhibition and miR-200b-3p/ZEB1 axis in human pancreatic cancer. International Journal of Oncology 2017; 50(1): 111 doi: 10.3892/ijo.2016.3772
|
| 4 |
Yong-Feng Guan, Xiu-Juan Liu, Xiao-Jing Pang, Wen-Bo Liu, Guang -Xi Yu, Yin -Ru Li, Yan-Bing Zhang, Jian Song, Sai-Yang Zhang. Recent progress of oridonin and its derivatives for cancer therapy and drug resistance. Medicinal Chemistry Research 2021; 30(10): 1795 doi: 10.1007/s00044-021-02779-6
|
| 5 |
Dahong Li, Tong Han, Jie Liao, Xu Hu, Shengtao Xu, Kangtao Tian, Xiaoke Gu, Keguang Cheng, Zhanlin Li, Huiming Hua, Jinyi Xu. Oridonin, a Promising ent-Kaurane Diterpenoid Lead Compound. International Journal of Molecular Sciences 2016; 17(9): 1395 doi: 10.3390/ijms17091395
|
| 6 |
Bowen Dong, Zirui Liang, Zhirong Chen, Bin Li, Lingling Zheng, Jianhua Yang, Hui Zhou, Lianghu Qu. Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation. Science China Life Sciences 2018; 61(9): 999 doi: 10.1007/s11427-018-9324-y
|
| 7 |
Yiping Wang, Hang Lv, Chunyan Dai, Xi Wang, Yifei Yin, Zhe Chen, Jun Yan Tao. Oridonin Dose-Dependently Modulates the Cell Senescence and Apoptosis of Gastric Cancer Cells. Evidence-Based Complementary and Alternative Medicine 2021; 2021: 1 doi: 10.1155/2021/5023536
|
| 8 |
Hua Luo, Chi Teng Vong, Hanbin Chen, Yan Gao, Peng Lyu, Ling Qiu, Mingming Zhao, Qiao Liu, Zehua Cheng, Jian Zou, Peifen Yao, Caifang Gao, Jinchao Wei, Carolina Oi Lam Ung, Shengpeng Wang, Zhangfeng Zhong, Yitao Wang. Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine. Chinese Medicine 2019; 14(1) doi: 10.1186/s13020-019-0270-9
|
| 9 |
Yanan Zhu, Lehao Wu, Yaxue Zhao, Zeyuan Wang, Jihong Lu, Yang Yu, Hua Xiao, Yan Zhang. Discovery of oridonin as a novel agonist for BRS-3. Phytomedicine 2022; 100: 154085 doi: 10.1016/j.phymed.2022.154085
|
| 10 |
Zhifang Gui, Shuquan Li, Xing Liu, Bin Xu, Jian Xu. Oridonin alters the expression profiles of MicroRNAs in BxPC-3 human pancreatic cancer cells. BMC Complementary and Alternative Medicine 2015; 15(1) doi: 10.1186/s12906-015-0640-5
|
| 11 |
Weiyan Cheng, Chuanhui Huang, Weifeng Ma, Xin Tian, Xiaojian Zhang. Recent Development of Oridonin Derivatives with Diverse Pharmacological Activities. Mini-Reviews in Medicinal Chemistry 2018; 19(2): 114 doi: 10.2174/1389557517666170417170609
|
| 12 |
Fanxing Xu, Xiang Gao, Haonan Li, Shengtao Xu, Xu Li, Xu Hu, Zhanlin Li, Jinyi Xu, Huiming Hua, Dahong Li. Hydrogen sulfide releasing enmein-type diterpenoid derivatives as apoptosis inducers through mitochondria-related pathways. Bioorganic Chemistry 2019; 82: 192 doi: 10.1016/j.bioorg.2018.10.002
|
| 13 |
Md. Shahid Sarwar, Yi-Xuan Xia, Zheng-Ming Liang, Siu Wai Tsang, Hong-Jie Zhang. Mechanistic Pathways and Molecular Targets of Plant-Derived Anticancer ent-Kaurane Diterpenes. Biomolecules 2020; 10(1): 144 doi: 10.3390/biom10010144
|
| 14 |
Claire B. Cummins, Xiaofu Wang, Christian Sommerhalder, Frederick J. Bohanon, Omar Nunez Lopez, Hong-Yan Tie, Victoria G. Rontoyanni, Jia Zhou, Ravi S. Radhakrishnan. Natural Compound Oridonin Inhibits Endotoxin-Induced Inflammatory Response of Activated Hepatic Stellate Cells. BioMed Research International 2018; 2018: 1 doi: 10.1155/2018/6137420
|
| 15 |
Zhongwei He, Xiangling Xiao, Shan Li, Yang Guo, Qiuyue Huang, Xin Shi, Xiaobo Wang, Ying Liu. Oridonin induces apoptosis and reverses drug resistance in cisplatin resistant human gastric cancer cells. Oncology Letters 2017; 14(2): 2499 doi: 10.3892/ol.2017.6421
|
| 16 |
Sankhadip Bose, Sabyasachi Banerjee, Arijit Mondal, Utsab Chakraborty, Joshua Pumarol, Courtney R. Croley, Anupam Bishayee. Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy. Cells 2020; 9(6): 1451 doi: 10.3390/cells9061451
|
| 17 |
Xia Li, Kai Wang, Gerun Wang, Binbin Cui, Shihao Song, Xiuyun Sun, Yinyue Deng, Giordano Rampioni, Eunhye Goo. Oridonin Attenuates Burkholderia cenocepacia Virulence by Suppressing Quorum-Sensing Signaling. Microbiology Spectrum 2022; 10(4) doi: 10.1128/spectrum.01787-22
|
| 18 |
Muhammad Asif Ali, Noohela Khan, Ahmad Ali, Hira Akram, Noushaba Zafar, Kinza Imran, Tooba Khan, Khushbukhat Khan, Muhammad Armaghan, Marta Palma‐Morales, Celia Rodríguez‐Pérez, Angela Caunii, Monica Butnariu, Solomon Habtemariam, Javad Sharifi‐Rad. Oridonin from Rabdosia rubescens: An emerging potential in cancer therapy – A comprehensive review. Food Science & Nutrition 2024; doi: 10.1002/fsn3.3986
|